Biowings Therapeutics

Biowings Therapeutics is a preclinical-stage biotechnology company focused on the discovery and development of next-generation proteasome inhibitors for the treatment of cancer and autoimmune diseases. The company's primary technological focus is the selective inhibition of the immunoproteasome, a specialized proteasome variant highly expressed in hematologic malignancies and immune cells. By utilizing a novel chemical scaffold, Biowings aims to overcome the clinical limitations and drug resistance associated with first- and second-generation proteasome inhibitors like bortezomib and carfilzomib. Their lead candidate, BW-101, is being developed to provide a more potent and selective therapeutic option for patients with refractory multiple myeloma. The company's approach seeks to improve the therapeutic index and safety profile for patients suffering from high-need inflammatory and oncological conditions.